Vivos recently announced the company has become the exclusive distributor of the NR6 Rhinomanometer from GM Instruments in the U.S. and Canada.
Vivos is focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults.
This is the only FDA approved 4-phase rhinomanometer available in the U.S. that calculates nasal airway resistance by measuring nasal flow and the pressure producing that flow, according to a press release.
This specialized diagnostic equipment evaluates nasal breathing and function in dental patients with sleep and breathing issues. The objective measurement of nasal breathing can be an essential data point in determining the appropriate breathing and sleep issue treatment path as well as a predictor of potential Continuous Positive Airway Pressure (CPAP) intolerance or other treatment failure.
The GM Instruments’ NR6 Rhinomanometer offers a quick, non-invasive test to measure the function of the nose during active breathing. Test results are used by Vivos-trained dentists and others to measure outcomes of improvement for pre- mid- and post-treatment of patients undergoing various treatment modalities.
There are also plans to use GM Instruments products as part of research protocols to improve and support the outcomes of Vivos products and methods for OSA diagnosis and treatment.
“Many medical problems such as OSA, overall lung function, and even spinal and posture issues are related to nasal resistance and poor breathing, and our breathing is disrupted before our sleep is disrupted,” said Dr. Karen Parker Davidson, RN, vice president of sales for GM-Instruments, North America, according to the release. “With this strong collaboration with Vivos, we believe we have the opportunity to change the standard of care for OSA to improve patient outcomes and manage their health with better testing and assessments.”
View Full Press Release